Ibex Investors’s Pacific Biosciences PACB Stock Holding History

Ibex Investors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-28,134	Closed	-$209K	–	117
2018 Q4	$209K	Buy	+28,134	New	+$178K	0.03%	149

Other funds holding PACB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Ibex Investors's PACB Position: Q1 2019 in Review

Ibex Investors sold out of Pacific Biosciences (PACB) in Q1 2019, closing a stake of 28,134 shares — an estimated $209K sold.

Ibex Investors first reported a position in PACB in Q4 2018 and held it in 1 quarter. The position peaked at $209K in Q4 2018. 160 funds tracked by Wall St. Rank hold PACB as of Q1 2019.

Ibex Investors reported no remaining Pacific Biosciences position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 28,134 Pacific Biosciences shares in Q1 2019, an estimated $209K.
Ibex Investors first reported a position in Pacific Biosciences in Q4 2018 and held it in 1 quarter.
Ibex Investors's Pacific Biosciences position peaked at $209K in Q4 2018.
160 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.